• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Sirion gains license to ophthalmic emulsion

Article

Tampa, FL-Sirion Therapeutics Inc. agreed to receive exclusive U.S. licensing rights to a topical ophthalmic emulsion containing difluprednate, a steroid compound that may treat inflammatory eye diseases.

Tampa, FL-Sirion Therapeutics Inc. agreed to receive exclusive U.S. licensing rights to a topical ophthalmic emulsion containing difluprednate, a steroid compound that may treat inflammatory eye diseases.

"We are excited about the potential that this product brings to Sirion," said Roger Vogel, MD, chief medical officer of Sirion. "We believe this strong steroid can fill a gap in the current treatment options for moderate and severe inflammatory diseases of the eye."

Under the agreement, Senju Pharmaceuticals will give Sirion rights to develop, use, obtain governmental approval, manufacture, sell, distribute, and promote difluprednate formulations as an ophthalmic emulsion and/or suspension throughout the United States.

Related Videos
John Saharek, president of ImprimisRX, speaks with Ophthalmology Times' David Hutton on three new products the company will be featuring during the American Academy of Ophthalmology's 2021 annual meeting
What keeps you up at night in ophthalmology: Part II
Chris Adams, Diopter Corp CEO
Ramin Valian, of Allergan, discusses pharmaceuticals in the glaucoma industry at Glaucoma 360
© 2024 MJH Life Sciences

All rights reserved.